Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + Lenalidomide + Rituximab in R/R FL or MZL
NCT04680052Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Apr 2021
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of tafasitamab in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Incyte. Started Apr 2021; status: active, not recruiting.
02
Drugs
tafasitamab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04680052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680052.